NASDAQ:MGNX MacroGenics Q3 2026 Earnings Results & Report $1.92 -0.05 (-2.28%) As of 02:46 PM Eastern This is a fair market value price provided by Massive. Learn more. MacroGenics was expected to report Q3 2026 earnings on November 12, 2026, after market closes. Analysts expected earnings of -$0.3151 per share on revenue of $39.18 million. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call7:00 AM ET MacroGenics EPS ResultsActual EPSN/AConsensus EPS -$0.3151Beat/MissN/AOne Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersMacroGenics Revenue ResultsActual RevenueN/AExpected Revenue$39.18 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) MacroGenics Earnings HeadlinesMacroGenics (NASDAQ:MGNX) Cut to Sell at Wall Street ZenNovember 17 at 3:42 AM | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Stock Now Rated "Hold" by Sell-Side BrokeragesNovember 16 at 2:01 AM | americanbankingnews.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 19 at 1:00 AM | Behind the Markets (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Thermo Fisher (TMO), MacroGenics (MGNX) and Diaceutics (OtherDIUXF)November 14, 2026 | theglobeandmail.comMacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate ProgressNovember 12, 2026 | markets.businessinsider.comMacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMSee More MacroGenics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MacroGenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MacroGenics and other key companies, straight to your email. Email Address About MacroGenicsMacroGenics (NASDAQ:MGNX) is a biotechnology company focused on discovering and developing antibody-based medicines, primarily for cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company works on its own drug candidates and collaborates with other pharmaceutical and biotechnology companies. Its research uses antibody-engineering technologies, including platforms designed to engage immune cells against tumors and to deliver therapeutic payloads to cancer cells. MacroGenics’ portfolio has included margetuximab, marketed as Margenza, an antibody treatment approved in the United States for certain patients with HER2-positive metastatic breast cancer. The company’s development programs and collaborations span multiple regions, with partners involved in advancing or commercializing therapies in international markets. MacroGenics continues to focus on developing antibody-based treatments for cancer.View MacroGenics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.